Who Supplies Metronidazole to India from FRANCE

Importing finished pharmaceutical formulations containing Metronidazole into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs possess a valid import license issued under Form 10. Additionally, the foreign manufacturer must be registered with CDSCO under Form 41. The Indian importer must obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). The application process involves submitting detailed product information, manufacturing licenses, and authorization letters from the foreign manufacturer. The timeline for obtaining these approvals can vary but typically ranges from 3 to 6 months, depending on the completeness of the application and regulatory processing times.

Imported pharmaceutical formulations containing Metronidazole must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian standards. Each batch requires a Certificate of Analysis (CoA) confirming adherence to the Indian Pharmacopoeia. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under India's climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. These inspections include sampling and testing, which can extend the clearance time by several days. If a batch fails quality testing, it may be subject to re-exportation, destruction, or other regulatory actions as deemed appropriate by CDSCO.

Between 2024 and 2026, CDSCO has implemented stricter regulations for the importation of pharmaceutical products to enhance drug safety and efficacy. Notably, on April 8, 2025, CDSCO mandated that all imported drugs, including finished formulations containing Metronidazole, must have both import registration and a license. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import landscape, encouraging domestic manufacturing and potentially reducing reliance on imports. Bilateral agreements between India and France have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined approval processes for French pharmaceutical products.

India imports finished Metronidazole formulations primarily due to the demand for specific dosage forms and branded products not manufactured domestically. The domestic production of Metronidazole is substantial; however, certain specialized formulations, such as extended-release tablets or combination therapies, are not produced locally. The market size for Metronidazole formulations in India is significant, with a growing demand driven by the prevalence of infections treatable by Metronidazole. The import dependency is influenced by factors such as patent protections, technological advancements, and the need for high-quality products that meet international standards.

The Basic Customs Duty (BCD) for HS Code 30049022, which covers Metronidazole formulations, is 10%. In addition to BCD, the Social Welfare Surcharge (SWS) is levied at 10% of the BCD, resulting in an effective duty of 11%. The Integrated Goods and Services Tax (IGST) is applicable at 12% on the assessable value, which includes the CIF (Cost, Insurance, and Freight) value plus the BCD and SWS. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) determines that imports are being dumped in the Indian market. Exemption notifications can reduce or eliminate certain duties; however, no specific exemptions are currently applicable to Metronidazole formulations from France. The total landed duty percentage combines these components, affecting the final cost of imported products.

India sources Metronidazole formulations from France due to the high quality and reliability of French pharmaceutical products. French manufacturers often offer patented formulations and specialized dosage forms that are not available from other suppliers. The competitive advantage of French suppliers includes adherence to stringent quality standards, advanced manufacturing technologies, and a reputation for producing high-quality pharmaceutical products. Other suppliers, such as China, Germany, and the United States, also export Metronidazole formulations to India; however, France's share in this market is notable due to these factors.

India imports Metronidazole formulations from France due to the availability of patented formulations and specialized dosage forms not produced domestically. French manufacturers offer high-quality products that meet international standards, which is crucial for treating infections effectively. The technological advancements and adherence to stringent quality controls in France provide a competitive edge, making French products desirable in the Indian market.

When compared to other origins such as China, Germany, and the United States, France offers superior quality and reliability in pharmaceutical manufacturing. French products are known for their adherence to international quality standards and innovative formulations. While other countries may offer competitive pricing, France's reputation for quality and consistency makes it a preferred choice for importing Metronidazole formulations into India.

Indian importers face several supply chain risks when sourcing Metronidazole formulations from France, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, closely monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for potential shipping delays or quality issues.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment